Many of our patients have experienced dramatic improvements in their overall health, even the ability to come off certain medicationsthey previously relied on
Eli Lilly is aggressively capitalizing on its significant first-mover advantage in the obesity market with its blockbuster GLP-1 drugs, Zepbound and Mounjaro
The Takeaway Obesity is linked to more active MS, and while weight loss hasnt been shown to reverse the disease, it may help reduce inflammation and make symptoms easier to manage
During a trial, one patient died by suicide so patients should also be monitored for depression and suicidal thoughts while taking it, according to the FDA.
You might expect GLP-1 users to gradually fade out, drifting off the meds all together
No insurance is required, and pricing remains flat regardless of dose increases